Oxford Biomedica is developing life-changing gene therapies for patients with high unmet medical needs. Our unique LentiVector® platform, a proprietary lentiviral vector gene delivery platform, has enabled the successful development of breakthrough gene and cell-based medicines, including the first approved CAR-T therapy in the US and in Europe. We have strong partnerships with leaders in the field, including Novartis, Orchard Therapeutics, Sanofi, Axovant, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations. Oxford Biomedica has a long and broad clinical and commercial track record in the gene therapy field spanning over 22 years. We were the first to administer lentiviral vector gene therapy directly to patients and the first FDA, EMA and PDMA-approved commercial supplier of lentiviral vectors in the world. Several hundreds of patients have safely received ex vivo and in vivo treatment with therapies that use our vectors. Our own portfolio of products includes candidates in the fields on oncology, ophthalmology and CNS disorders. We continuously invest in our platform and plan to continue our preclinical R&D to discover new products.